hogfan's picks

[hogfan2]

$ATHX...Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. The company currently has five clinical stage programs involving MultiStem, including those for treating inflammatory bowel disease (partnered with Pfizer Inc.), ischemic stroke, damage caused by myocardial infarction and for the prevention of graft-versus-host disease. Athersys has additional pharmaceutical programs in the metabolic and neurological areas, and a broad international network of collaborations with leading clinical and research institutions. hide
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Jason Kolbert, Maxim Group (12/29/14) "Athersys Inc. is closing in on a major milestone. . .the company announced that it has concluded enrollment of its Phase 2 (~N=140) control versus active stroke trial. . .our research and channel checks leave us enthused about stroke data in Q1/15. We believe the probability skew is positive for Athersys, and the outcome has the potential to be transformative for both the company and patients."
Wall Street Titan, Seeking Alpha (11/26/14) "Athersys Inc. is doing everything within its power to position itself to grab a Japanese revenue opportunity that would place an entirely new valuation on the company. The beauty of this legislation, from a risk perspective, is that Athersys does not need a home run from its stroke data to start earning substantial revenues in Japan. The company has already demonstrated safety. . .with an enterprise value of only $78M it certainly seems that Athersys shares have substantial room for upside, based on the stroke opportunity and their other programs entering phase 2 shortly, including graft-versus-host disease and acute myocardial infarction."
Christian Glennie, Edison Investment Research (11/24/14) "Athersys Inc. is developing MultiStem, an allogeneic stem cell product (bone marrow-derived, multipotent adult progenitor cells or MAPCs). Results from a 140-patient Phase 2 study in ischaemic stroke are expected in Q1/15, with recruitment to complete in Q4/14. Positive results could be transformational for the treatment of stroke patients and for Athersys' market valuation. . .the company is well positioned in terms of its stage of development and the profile of its MAPCs, in terms of safety, high dose (>1 billion cells), and convenient mode of delivery. The MAPCs appear to be substantially differentiated from other MSCs."
Jason Kolbert, Maxim Group (11/10/14) "Athersys Inc.ended Q3/14 with $32M in cash, plenty of capital to fund the company through its next major catalyst, results of the Phase 2 stroke trial, where enrollment is almost complete. . .we are excited for results from its Phase 2 stroke trial. We are hopeful of good data (positive bias) and believe good data will be transformational to Athersys and the field."
The Life Sciences Report Interview with R. Lee Buckler (10/22/14) "Athersys Inc. has announced a desire to move into Japan, and I know it is putting boots on the ground in the country to develop a strategy there. Back in January, the company announced some new Japanese patents in graft-versus-host disease and autoimmune diseases, such as inflammatory bowel diseases." More >
more comments
http://www.thelifesciencesreport.com/pub/co/4435